Project Application Form for the Screening Facility 2015
Please complete the following sections.
1. Project title.
2. Applicants and contact details (email, telephone).
Institution:
Lead Applicant:
Additional Researchers:
3. Researcher statement.
If you have a nominated researcher to work on the project, please include a
statement from them below, detailing why this work is of interest to them, how it
fits in which their existing project(s), and what they will gain from engaging on the
project.
4. Proposal summary.
Please provide detailed scientific background to the proposed project, covering the
criteria outlined. Please also include any relevant preliminary and supporting
data/figures.
Need
Aims and specific hypotheses
Proposed method
Strategy for follow up
5. Current status. Please delete the following as appropriate, or indicate if unknown.
This allows us to assess the current status of your assay and assign a timeline
accordingly.
Cells are certified mycoplasma free
Assay is operational in a 96 well plate - please
attach evidence supporting this, if available
Readily cultured with good adherence?
Starting cell seeding density
Any known issues with cell seeding i.e. edge
effects, uneven seeding within well?
Y/N
Y/N
Y/N
XXX cells/well
Y/N
What is the proposed total time course of assay?
Assay specifics - do you wish to consider
culturing:
Under hypoxic vs normoxic conditions?
Under low vs high serum conditions?
With an additional reagent e.g. a drug?
Another condition? Please state:
Output desired?
Nuclear count (Operetta)
Metabolic viability (rezasurin, fluorescence)
Additional antibodies/stains to be included?
Please state:
Multiparametric phenotypic characterisation?
Y/N
Y/N
Y/N
Y/N
Y/N
None/cellular/nuclear/both?
Size
Shape
Intensity
Proximity
Other? Please state:
Y/N
Y/N
Y/N
Y/N
If you are requesting screening of siRNA libraries, please complete below:
siRNA controls
Suitable siRNA control for desired phenotype
identified? Please state:
If 'no', have potential controls been identified?
Please state:
If siRNA control is unavailable, is a drug control
available? Please state:
Are any additional reagents required for this
screen i.e. antibodies, drugs, matrigel?
If 'Y', please state:
Y/N
Are reagents readily available in sufficient
quantities?
If you are requesting screening in conjunction with a nominated drug candidate(s) e.g. in
conjunction with a specific chemotherapeutic, please complete below:
Drugs
How many drugs would you like to screen?
What drugs would you like to screen?
Are the targets of the drugs known?
Are the targets expressed in the cell lines of
interest?
Are drugs soluble in DMSO?
What is the maximal concentration dissolved?
Have dose response curve(s) i.e. EC50 been
determined?
Y/N
Y/N
Y/N
Y/N
If so, please attach example dose response
curve(s)
Do you have a scientist available to work with us on this project?
Y/N
This involves a partial (~20%) time commitment during assay development, a 100% time
commitment while screening, and a commitment to hit validation post-screening.
The screening facility does have some capacity to engage on smaller projects in-house
without the collaborating group providing a researcher: we hope that this will make us more
accessible to new group leaders, but it is also an option for other groups.
The screening facility will consider requests for projects to be conducted in-house on a
case-by-case basis, and will offer support wherever possible.
Would you like your project to be considered for screening in-house?
Please provide any additional information below.
Y/N
6. Screening collections
The following siRNA and drug collections are available for screening. In addition, we can also
offer support in generating your own, custom built library on request. Gene lists can be
downloaded from the Beatson Intranet, or can be provided if required.
Please state which libraries you would like to screen:
1. siRNA
 Human
 Mouse



2.


Y/N
Y/N
Whole genome
Pre-defined focused set(s) (see below)
Custom focused set(s)
Y/N
Y/N
Y/N
Drugs
Drug Repurposing set(s)
NIH Approved Oncology drugs set
Y/N
Y/N
If focused sets requested, which ones would you like to screen?
Pre-defined:
 Kinase
 GPCR
 Phosphatase
 Ion Channel
 Drug Targets
 Protease
 Ubiquitination 1 (Cullins, E1, E2, HECT E3 Ligases)
 Ubiquitination 2 (F-box, SOCS box E3 Ligases)
 Ubiquitination 3 (RING finger and RING finger-like E3 Ligases)
Y/N
Y/N
Y/N
Y/N
Y/N
Y/N
Y/N
Y/N
Y/N
Custom
 Your own library
 Lipid metabolism
 Metabolism 1800
 Mouse metabolism (494 genes)
Y/N
Y/N
Y/N
Y/N
The Metabolism1800 set was purchased as a Beatson-wide collaboration, and contains 1800
genes pertaining to cellular metabolism in general. Researchers have access to the lipid
metabolism and mouse metabolism custom libraries courtesy of Eyal Gottlieb.
There are other custom sets within the Beatson Institute, but they are not owned by us. If
you are interested in sets covering the following, please contact the corresponding PI.
 Epigenetics library – Peter Adams
 Actin/metastasis library - Laura Machesky
 Rab proteins and related genes – Iain MacPherson/Jim Norman
Drug Libraries
We have a library of approved oncology drugs (n=114) from the NIH, and three collections of
developed/marketed drugs for indications unrelated to cancer. All collections are designed
to support drug repurposing approaches and are available for screening. Please state which
collections you would like to screen:




NIH Approved Oncology Collection (n=114)
NIH Clinical Collection (n=727)
Pfizer LOPAC collection (n=91)
Selleckchem FDA Approved Drug Library (n=420)
Y/N
Y/N
Y/N
Y/N
7. Please provide any relevant references.
8. To facilitate scheduling, please answer the following as appropriate:
 This project is (or will be) part of a grant application
If Yes, please indicate:
 The funding body and scheme
Y/N
 when do you expect to know the outcome
mm/yy
 will the project proceed if the grant application is not successful
Y/N
For any informal enquiries or discussions about projects, please email Emma
Shanks (e.shanks@beatson.gla.ac.uk)
Thank you for taking the time to complete this form.